A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin

Circulation: Heart Failure

Volumn 6, Issue 4, 2013, Pages 833-844

  Liu, Wei ^a   Zi, Min ^b   Tsui, Hoyee ^a,b   Chowdhury, Sanjoy K ^a   Zeef, Leo ^a   Meng, Qing Jun ^a   Travis, Mark ^a   Prehar, Sukhpal ^b   Berry, Andrew ^b   Hanley, Neil A ^b   Neyses, Ludwig ^b   Xiao, Rui Ping ^c   Oceandy, Delvac ^b   Ke, Yunbo ^d   Solaro, R John ^d   Cartwright, Elizabeth J ^b   Lei, Ming ^b   Wang, Xin ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c PEKING UNIVERSITY   (China)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cardiac hypertrophy; Fibrosis; FTY 720; NFAT; Periostin

Indexed keywords

COLLAGEN; FINGOLIMOD; INTERLEUKIN 6; OSTEOPROTEGERIN; PERTUSSIS TOXIN; PLEIOTROPHIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; CELL ADHESION MOLECULE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; POSTN PROTEIN, MOUSE; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORONARY HEMODYNAMICS; CYTOPLASM; ECHOCARDIOGRAPHY; FIBROBLAST; FIBROSING ALVEOLITIS; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART PERFORMANCE; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE PRESSURE; HEART WEIGHT; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; INFERIOR CAVA VEIN OBSTRUCTION; MACROPHAGE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL CULTURE; CYTOLOGY; DRUG EFFECT; FIBROSIS; FTY-720; HEMODYNAMICS; NEWBORN; NFAT; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

CARDIAC HYPERTROPHY; FIBROSIS; FTY-720; NFAT; PERIOSTIN;

ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELL ADHESION MOLECULES; CELLS, CULTURED; FIBROBLASTS; FIBROSIS; HEMODYNAMICS; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SPHINGOSINE; VENTRICULAR PRESSURE;

EID: 84884719159     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.000123     Document Type: Article

References (35)

1. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327-334.
2. Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD, Rockman HA, Kass DA, Molkentin JD, Sussman MA, Koch WJ, Koch W; American Heart Association Council on Basic Cardiovascular Sciences, Council on Clinical Cardiology, and Council on Functional Genomics and Translational Biology. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res. 2012;111:131-150.
3. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79.
4. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589.
5. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007;6:617-635.
6. Koitabashi N, Kass DA. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2012;9:147-157.
7. Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J. 2004;45:991-997.
8. Kahan BD. FTY720: from bench to bedside. Transplant Proc. 2004;36(2 Suppl):531S-543S.
9. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005;108:308-319.
10. Liu W, Zi M, Naumann R, Ke Y, Ulm S, Jin J, Taglieri DM, Prehar S, Gui J, Xiao RP, Neyses L, Soralo J, Cartwright EJ, Lei M, Wang X. Pak1 is a novel signaling regulator attenuating cardiac hypertrophy in mice. Circulation. 2011;124:2702-2715.
11. Schmouder R, Serra D, Wang Y, Kovarik JM, DiMarco J, Hunt TL, Bastien MC. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006;46:895-904.
12. Sensken SC, Stäubert C, Keul P, Levkau B, Schöneberg T, Gräler MH. Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. Cell Signal. 2008;20:1125-1133.
13. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol. 2002;14:569-575.
14. Adams JW, Brown JH. G-proteins in growth and apoptosis: lessons from the heart. Oncogene. 2001;20:1626-1634.
15. Salazar NC, Chen J, Rockman HA. Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta. 2007;1768:1006-1018.
16. Berk BC, Fujiwara K, Lehoux S. ECM remodelling in hypertrophive heart disease. J Clin Invest. 2007; 117:568-575.
17. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res. 2007;74:207-212.
18. Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-791.
19. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem. 1994;216:276-284.
20. Snider P, Hinton RB, Moreno-Rodriguez RA, Wang J, Rogers R, Lindsley A, Li F, Ingram DA, Menick D, Field L, Firulli AB, Molkentin JD, Markwald R, Conway SJ. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res. 2008;102:752-760.
21. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, Conway SJ. Origin of cardiac fibroblasts and the role of periostin. Circ Res. 2009;105:934-947.
22. Sidhu SS, Yuan S, Innes AL, Kerr S, Woodruff PG, Hou L, Muller SJ, Fahy JV. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA. 2010;107:14170-14175.
23. Lorts A, Schwanekamp JA, Baudino TA, McNally EM, Molkentin JD. Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc Natl Acad Sci USA. 2012;109:10978-10983.
24. Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N. Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. Biochim Biophys Acta. 2008;1781:483-488.
25. Kennedy S, Kane KA, Pyne NJ, Pyne S. Targeting sphingosine- 1-phosphate signalling for cardioprotection. Curr Opin Pharmacol. 2009;9:194-201.
26. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 2002;27:92-98.
27. Conway SJ, Molkentin JD. Periostin as a heterofunctional regulator of cardiac development and disease. Curr Genomics. 2008;9:548-555.
28. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW, Dorn GW II, Conway SJ, Aronow BJ, Robbins J, Molkentin JD. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res. 2007;101:313-321.
29. Lorts A, Schwanekamp JA, Elrod JW, Sargent MA, Molkentin JD. Genetic manipulation of periostin expression in the heart does not affect myocyte content, cell cycle activity, or cardiac repair. Circ Res. 2009;104:e1-e7.
30. Hinz B. Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep. 2009;11:120-126.
31. Goodwin A, Jenkins G. Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. Biochem Soc Trans. 2009;37:849-854.
32. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95-103.
33. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007;115:501-508.
34. Hakuno D, Kimura N, Yoshioka M, Mukai M, Kimura T, Okada Y, Yozu R, Shukunami C, Hiraki Y, Kudo A, Ogawa S, Fukuda K. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest. 2010;120:2292-2306.
35. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, Nayor M, Konno T, Gorham JM, Wolf CM, Kim JB, Schmitt JP, Molkentin JD, Norris RA, Tager AM, Hoffman SR, Markwald RR, Seidman CE, Seidman JG. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-β. J Clin Invest. 2010;120:3520-3529.